arrow_back Back to App

Assessment of US Government Efforts Against Antimicrobial Resistance

This act mandates the Comptroller General of the United States to prepare a report on federal government efforts to combat antimicrobial resistance. The report aims to identify duplications, improve coordination, and evaluate past results, potentially leading to more efficient use of public funds in research for new drugs and therapies, impacting citizens' future health security.
Key points
The U.S. government will assess its actions against antimicrobial resistance, potentially improving research and treatment effectiveness.
The report will identify duplicated programs and resources, which could lead to savings and better use of taxpayer money.
Recommendations will be made for better coordination of federal efforts, potentially accelerating the development of new treatments like phage therapy.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7436
Sponsor: Rep. Griffith, H. Morgan [R-VA-9]
Process start date: 2024-02-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Antimicrobial Resistance Research Assessment Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7436.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-02-23.

What are the main provisions?

Key points include:

  • The U.S. government will assess its actions against antimicrobial resistance, potentially improving research and treatment effectiveness.
  • The report will identify duplicated programs and resources, which could lead to savings and better use of taxpayer money.
  • Recommendations will be made for better coordination of federal efforts, potentially accelerating the development of new treatments like phage therapy.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Griffith, H. Morgan [R-VA-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health